{
    "nct_id": "NCT03682029",
    "official_title": "Epigenetics, Vitamin C, and Abnormal Hematopoiesis - Role of Vitamin C in Epigenetic Regulation in Hematopoiesis Sub-Study on CCUS, Low-Risk MDS, and CMML-0/1",
    "inclusion_criteria": "A diagnosis of CCUS:\n\n* Persistent cytopenia for > 6 months defined as hgb < 11.3 g/dL (7 mmol/L) in women and hgb < 12.9 g/dL (8 mmol/L) in men, thrombocyte count < 150 x 10^9/L or neutrophil count < 1.8 x 10^9/L\n* Normal cytogenetics (with the exception of deletion of the Y chromosome which can be accepted)\n* A bone marrow morphology that is not diagnostic of MDS or any other malignancy\n* Other common causes of cytopenia (vitamin or other deficiencies, virus infection, etc.) have been ruled out\n* Hematolytic conditions have been ruled out\n* The presence of a detectable mutation in genes recurrently affected in myeloid malignancy representing a clonal marker (excluding germline mutations)\n\nOR\n\nA diagnosis of MDS as according to World Health Organization (WHO) 2016 diagnostic criteria\n\n• Revised international prognostic scoring system (IPSS-R) risk score ≤ 3 AND bone marrow blast percentage < 5 defining low-risk\n\nOR\n\nA diagnosis of CMML-0 or -1 as according to WHO 2016 diagnostic criteria\n\nAND\n\n(All diagnostic categories) The presence of a detectable mutation in genes recurrently affected in myeloid malignancy representing a clonal marker (excluding germline mutations)\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Unwillingness to discontinue any and all use of vitamin C medication/supplementation including multivitamin at least 24 hours prior to Baseline investigations and sampling\n* Lack of ability to understand the information given, or lack of willingness to sign a written informed consent document\n* Treatment with chemotherapy within the past 6 months\n* Patients receiving active treatment for their myeloid malignancy, including investigational agents, with the exception of granulocyte colony-stimulating factor (G-CSF) and erythropoietin\n* History of allergic reactions to ascorbic acid\n* Unwillingness to comply with all aspects of the protocol",
    "miscellaneous_criteria": ""
}